Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Average Rating of “Hold” by Brokerages

Revance Therapeutics, Inc. (NASDAQ:RVNC) has received a consensus rating of “Hold” from the nine analysts that are covering the stock, MarketBeat Ratings reports. Eight analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $8.39.

RVNC has been the topic of a number of recent research reports. StockNews.com initiated coverage on Revance Therapeutics in a report on Sunday. They issued a “hold” rating on the stock. Mizuho decreased their price objective on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a research note on Tuesday, December 10th. Barclays cut their price objective on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research note on Monday, December 23rd. HC Wainwright restated a “neutral” rating and set a $6.60 target price on shares of Revance Therapeutics in a research note on Friday, November 8th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research report on Friday, November 8th.

Revance Therapeutics Stock Up 1.0 %

Shares of NASDAQ:RVNC opened at $3.09 on Wednesday. The stock has a market capitalization of $322.57 million, a PE ratio of -1.60 and a beta of 0.86. The firm’s 50 day moving average price is $3.91 and its 200-day moving average price is $4.50. Revance Therapeutics has a twelve month low of $2.30 and a twelve month high of $8.98.

Revance Therapeutics (NASDAQ:RVNC) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The business had revenue of $59.88 million for the quarter, compared to analyst estimates of $67.73 million. Analysts expect that Revance Therapeutics will post -1.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Revance Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of RVNC. Arizona State Retirement System boosted its position in shares of Revance Therapeutics by 27.6% during the second quarter. Arizona State Retirement System now owns 27,716 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 5,996 shares during the last quarter. Sei Investments Co. lifted its stake in Revance Therapeutics by 52.5% in the 2nd quarter. Sei Investments Co. now owns 22,167 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 7,628 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Revance Therapeutics by 64.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,161 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 7,890 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Revance Therapeutics by 29.4% during the second quarter. The Manufacturers Life Insurance Company now owns 42,296 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 9,601 shares in the last quarter. Finally, Certuity LLC bought a new stake in shares of Revance Therapeutics in the second quarter worth about $26,000. Institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.